Clinical Trials Logo

Filter by:
NCT ID: NCT00113815 Completed - Epilepsy Clinical Trials

Topiramate as Adjunctive Therapy in Infants 1-24 Months for the Control of Partial Onset Seizures

Start date: May 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the tolerability, safety and efficacy of topiramate in infants with refractory partial onset seizures (POS).

NCT ID: NCT00113308 Completed - Clinical trials for Arthritis, Rheumatoid

COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis

Start date: June 2005
Phase: Phase 3
Study type: Interventional

This study is being conducted to find out if an investigational drug called GW406381 can help people with rheumatoid arthritis.

NCT ID: NCT00111670 Completed - Clinical trials for Diabetes Mellitus Type 2

A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes

Start date: June 2005
Phase: Phase 2
Study type: Interventional

This study will assess the efficacy, safety and tolerability of DPP-IV Inhibitor compared to placebo in patients with type 2 diabetes. The anticipated time on study treatment is < 3 months and the target sample size is 100-500 individuals.

NCT ID: NCT00111189 Completed - Schizophrenia Clinical Trials

A Study of the Efficacy (Effectiveness) of Paliperidone Palmitate in the Prevention of Recurrence of the Symptoms of Schizophrenia.

Start date: February 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of paliperidone palmitate compared with placebo in the prevention of recurrence of the symptoms of schizophrenia and to assess the safety and tolerability of paliperidone palmitate in patients with stable and symptomatic schizophrenia. The placebo used in this study was a nutritional substance known as 20% Intralipid emulsion given to patients requiring intravenous feedings.

NCT ID: NCT00110877 Completed - HIV Infection Clinical Trials

TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients

Start date: April 2005
Phase: Phase 3
Study type: Interventional

Study TMC114-C214 is a randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114 boosted with low dose ritonavir (RTV) versus Kaletra (LPV)/RTV in lopinavir-naïve treatment-experienced HIV-1 infected patients.

NCT ID: NCT00110305 Completed - Clinical trials for Human Immunodeficiency Virus Type 1

A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines

Start date: June 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the dose-response relationship of antiviral activity after 48 weeks treatment with 3 different dose regimens of TMC278.

NCT ID: NCT00109408 Completed - Clinical trials for Rheumatoid Arthritis

A Study to Assess the Safety and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis

Start date: July 2005
Phase: Phase 3
Study type: Interventional

This 2 arm study will assess the safety and efficacy of tocilizumab monotherapy versus methotrexate in patients with active rheumatoid arthritis (RA). Patients will be randomized to receive tocilizumab 8mg/kg iv every 4 weeks plus placebo po weekly, or methotrexate 7.5-20mg po weekly plus placebo iv every 4 weeks. The anticipated time on study treatment is 3-12 months and the target sample size is 500+ individuals.

NCT ID: NCT00108914 Completed - Clinical trials for Rhinitis, Allergic, Perennial

Perennial Allergic Rhinitis Study In Pediatric Subjects

Start date: February 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if the investigational drug is effective and safe in children with perennial allergic rhinitis.

NCT ID: NCT00106808 Completed - Clinical trials for Type 2 Diabetes Mellitus

Study of Muraglitazar Versus Pioglitazone in Type 2 Diabetes

Start date: August 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare Muraglitazar and Pioglitazone in patients with Type 2 Diabetes. Both the safety and blood sugar lowering effects of these treatments will be studied.

NCT ID: NCT00106574 Completed - Clinical trials for Rheumatoid Arthritis

A Study to Assess the Effect of Tocilizumab + DMARD Therapy on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis

Start date: April 2005
Phase: Phase 3
Study type: Interventional

This 2 arm study will compare the safety and efficacy, with regard to reduction of signs and symptoms, of tocilizumab versus placebo in combination with traditional Disease-Modifying Anti-Rheumatic Drug (DMARD) therapy in patients with moderate to severe active rheumatoid arthritis (RA) who have had an inadequate response to current DMARD therapy. Patients will be randomized to receive tocilizumab 8mg/kg iv or placebo iv every 4 weeks, in conjunction with stable DMARD therapy. The anticipated time on study treatment is 3-12 months, and the target sample size is 500+ individuals.